There is no argument that Lambert can articulate his points better than you or I can. I'm in agreement with what he has said for the most part. I gave him a thumbs up as well.

IMO RG is in a position where he is caught in the middle for now. He's stuck with the agreement with TPL over the MMP. I have to assume that the licensing agreement with TPL is OK and the licensing effort and ultimate success of the MMP hangs on the USPTO reexamination process.

The BOD's hired RG and now he is supposed to try and remove them when he himself is not even a member of the BOD? I don't know how he is supposed to accomplish this at this time. It would seem to me that RG's energies would be better spent trying to do what he was hired to do and IMO that is to build PTSC from the ground up with mergers and aquisitions to diversify PTSC's revenue stream from sole dependence on the MMP to products from PDSG for the future. This is what he is attempting to do imo. Has he made the right decisions surrounding the PDSG products? Time will tell.

My point that I am trying to make is that at this point in time PTSC is a big question mark for investers and it's success ultimately depends on clearing at least one of the two key hurdles, any one of which imo would move the share price significantly. The first being the USPTO reexamination and the second being the sales of PDSG products. Until then PTSC is a big risk especially due to it's past lack of accomplishment. It truly is a gamble "a crap shoot" for investors leary of risk in todays economic climate.

Ultimately PTSC will sink or swim and that imo is not dependent on the management style of RG, but is in the control of the USPTO and government agencies and hospitals that will choose to purchase or not purchase PDSG products nearly all of which is out of RG's hands. RG has positioned PTSC for this market with very little to work with. I have to assume he has reviewed the agreement with TPL concerning the MMP and finds it acceptable at this point in time and he must also be comfortable with the BOD as it stands which does not appear to be getting in his way.

The frustration for long time investors is waiting for the USPTO to complete it's reexamination and the time it's taking to land orders for the PDSG products. Also investors kicking themselves for not taking advantage of the SP which rose from pennies to dollars which proved to be premature in light of the USPTO impact on the MMP.

All the best,

Steve